Lipoprotein-Associated Phospholipase A2 Is an Independent Predictor of Incident Coronary Heart Disease in an Apparently Healthy Older Population. The Rancho Bernardo Study

Journal of the American College of Cardiology

Volumn 51, Issue 9, 2008, Pages 913-919

  Daniels, Lori B ^a   Laughlin, Gail A ^b   Sarno, Mark J ^c   Bettencourt, Ricki ^b   Wolfert, Robert L ^c   Barrett Connor, Elizabeth ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c diaDexus Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ANGINA PECTORIS; ARTICLE; ATHEROGENESIS; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYDROLYSIS; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; AGED, 80 AND OVER; CALIFORNIA; CORONARY ARTERY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 39549091690     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.10.048     Document Type: Article

References (20)

1. Tjoelker L.W., Eberhardt C., Unger J., et al. Plasma platelet-activating factor acetylhydrolase is a secreted phospholipase A2 with a catalytic triad. J Biol Chem 270 (1995) 25481-25487
2. Hakkinen T., Luoma J.S., Hiltunen M.O., et al. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol 19 (1999) 2909-2917
3. Kolodgie F.D., Burke A.P., Skorija K.S., et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 26 (2006) 2523-2529
4. Yang E.H., McConnell J.P., Lennon R.J., et al. Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol 26 (2006) 106-111
5. Packard C.J., O'Reilly D.S., Caslake M.J., et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention study group. N Engl J Med 343 (2000) 1148-1155
6. Koenig W., Khuseyinova N., Lowel H., Trischler G., and Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 110 (2004) 1903-1908
7. Ballantyne C.M., Hoogeveen R.C., Bang H., et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 109 (2004) 837-842
8. Blake G.J., Dada N., Fox J.C., Manson J.E., and Ridker P.M. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol 38 (2001) 1302-1306
9. Oei H.H., van der Meer I.M., Hofman A., et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam study. Circulation 111 (2005) 570-575
10. Rose G.A. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull World Health Organ 27 (1962) 645-658
11. Diabetes Drafting Group. Prevalence of small vessel and large vessel disease in diabetic patients from 14 centres. The World Health Organisation Multinational Study of Vascular Disease in Diabetics. Diabetes drafting group. Diabetologia 28 Suppl (1985) 615-640
12. Reid D.D., Hamilton P.J., McCartney P., Rose G., Jarrett R.J., and Keen H. Smoking and other risk factors for coronary heart-disease in British civil servants. Lancet 2 (1976) 979-984
13. National Heart and Lung Institute Lipid Research Clinics Program Laboratory Methods Committee. Manual of Laboratory Operations: Lipid and Lipoprotein Analysis. 2nd edition (1974), US Government Printing Office, Washington, DC DHEW publication no. 75-628
14. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
15. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus (1999), World Health Org, Geneva
16. Garrett J. Calculation of Adjusted Means and Proportions, 2001. http://www.stata.com/stb/stb24/sg33/ Accessed January 28, 2007.
17. Chang I.M., Gelman R., and Pagano M. Corrected group prognostic curves and summary statistics. J Chronic Dis 35 (1982) 669-674
18. DeLong E.R., DeLong D.M., and Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44 (1988) 837-845
19. Ballantyne C.M., Hoogeveen R.C., Bang H., et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 165 (2005) 2479-2484
20. Iribarren C., Gross M.D., Darbinian J.A., Jacobs Jr. D.R., Sidney S., and Loria C.M. Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study. Arterioscler Thromb Vasc Biol 25 (2005) 216-221